• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Maxim Group initiated coverage on Alterity Therapeutics with a new price target

    12/12/24 8:39:51 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHE alert in real time by email
    Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00
    Get the next $ATHE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATHE

    DatePrice TargetRatingAnalyst
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    12/12/2024$8.00Buy
    Maxim Group
    8/20/2021$4.00Speculative Buy
    Benchmark
    More analyst ratings

    $ATHE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alterity Therapeutics downgraded by The Benchmark Company

      The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

      2/3/25 7:02:17 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Maxim Group initiated coverage on Alterity Therapeutics with a new price target

      Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00

      12/12/24 8:39:51 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Benchmark initiated coverage on Alterity Therapeutics with a new price target

      Benchmark initiated coverage of Alterity Therapeutics with a rating of Speculative Buy and set a new price target of $4.00

      8/20/21 7:25:55 AM ET
      $ATHE
      Biotechnology: Pharmaceutical Preparations
      Health Care